Oxford Biomedica (LON:OXB) Stock Keeps Buy Rating at Jefferies Financial Group

Oxford Biomedica (LON:OXB)‘s stock had its “buy” rating reaffirmed by research analysts at Jefferies Financial Group in a research note issued to investors on Monday, MarketBeat Ratings reports. They presently have a GBX 827 target price on the biopharmaceutical company’s stock. Jefferies Financial Group‘s price target indicates a potential upside of 57.52% from the company’s previous close.

OXB has been the topic of several other research reports. Royal Bank Of Canada reaffirmed an “outperform” rating and set a GBX 900 price target on shares of Oxford Biomedica in a research note on Tuesday, September 1st. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 595 target price on shares of Oxford Biomedica in a report on Wednesday, September 2nd. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, Oxford Biomedica has an average rating of “Moderate Buy” and an average price target of GBX 818.

Oxford Biomedica Trading Up 2.1%

Shares of LON:OXB traded up GBX 11 during mid-day trading on Monday, reaching GBX 525. 7,696,761 shares of the company were exchanged, compared to its average volume of 1,080,181. The firm’s 50-day simple moving average is GBX 494.55 and its 200 day simple moving average is GBX 563.32. Oxford Biomedica has a 1 year low of GBX 420 and a 1 year high of GBX 952. The firm has a market cap of £635.50 million, a price-to-earnings ratio of -16.43 and a beta of 1.11. The company has a debt-to-equity ratio of 273.08, a current ratio of 2.21 and a quick ratio of 1.67.

Oxford Biomedica (LON:OXB) last released its quarterly earnings results on Wednesday, September 23rd. The biopharmaceutical company reported GBX (30.39) EPS for the quarter. Oxford Biomedica had a negative return on equity of 54.51% and a negative net margin of 23.23%. Equities research analysts forecast that Oxford Biomedica will post -31.08 EPS for the current year.

Insider Buying and Selling at Oxford Biomedica

In other Oxford Biomedica news, insider Roch Doliveux bought 20,250 shares of the business’s stock in a transaction that occurred on Wednesday, September 23rd. The shares were bought at an average price of GBX 505 per share, for a total transaction of £102,262.50. 25.83% of the stock is currently owned by corporate insiders.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.